Regeneron scientists discover key to excess bone growth in rare disease
September 02, 2015 at 14:00 PM EDT
CHICAGO, Sept 2 (Reuters) - Scientists at U.S. biotechnology company Regeneron Pharmaceuticals researching a rare genetic disease that traps sufferers in a second skeleton have discovered a treatment that shuts down excessive bone growth in mice engineered to develop the illness.